Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week safety, efficacy, pharmacodynamic, and pharmacokinetic study of teduglutide in Japanese pediatric short bowel syndrome patients
2020-005791-35Phase 3
- Sponsor
- Takeda
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Primary endpoint: Change in Parenteral Nutrition/Intravenous Fluids (PN/IV) Support.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2020-005791-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005791-35.